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Available online 4 April 2016PDGF-BB/PDGFR-ββ signaling plays very crucial roles in the process of many diseases such as liver ﬁbrosis. How-
ever, drug candidateswith selective afﬁnities for PDGF-B/PDGFR-β remain deﬁcient. Here,we identiﬁed a natural
cyclopeptide termed destruxin A5 that effectively inhibits PDGF-BB-induced PDGFR-β signaling. Interestingly
and importantly, the inhibitory mechanism is distinct from the mechanism of tyrosine kinase inhibitors because
destruxin A5 does not have the ability to bind to the ATP-binding pocket of PDGFR-β. Using Biacore T200 tech-
nology, thermal shift technology, microscale thermophoresis technology and computational analysis, we con-
ﬁrmed that destruxin A5 selectively targets the PDGF-B/PDGFR-β interaction interface to block this signaling.
Additionally, the inhibitory effect of destruxin A5 on PDGF-BB/PDGFR-ββ signaling was veriﬁed using in vitro,
ex vivo and in vivomodels, inwhich the extent of liver ﬁbrosis was effectively alleviated by destruxin A5. In sum-
mary, destruxin A5 may represent an efﬁcacious and more selective inhibitor of PDGF-BB/PDGFR-ββ signaling.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Liver ﬁbrosis1. Introduction
Platelet-derived growth factor receptor-beta (PDGFR-β) is a cell sur-
face receptor tyrosine kinase (Arora and Scholar, 2005). The biological
effect of PDGFR-β is initiated through binding to its ligands PDGF-B or
PDGF-D (Andrae et al., 2008; Borkham-Kamphorst et al., 2015; Kondo
et al., 2013). Accumulating documents have revealed that PDGF-B, as
the crucial ligand of PDGFR-β, binds to the extracellular domain of
PDGFR-β to promote its dimerization, which initiates PDGF-BB/
PDGFR-ββ signaling (Shim et al., 2010). The structure of the PDGF-B/
PDGFR-β complex revealed that PDGFR-β is bound by two PDGF-B
promoters, and the interface of the PDGF-B/PDGFR-β complex is pre-
dominantly hydrophobic (Shim et al., 2010).
Excessively enhanced PDGF-BB/PDGFR-ββ signaling is an important
feature of liver ﬁbrosis (Kocabayoglu et al., 2015). The underlying cellu-
lar mechanisms of liver ﬁbrosis principally involve the activation ofpartate aminotransferase; BDL,
ptor; FBS, fetal bovine serum;
; HAS, human serum albumin;
factor; PDGFR, platelet-derived
units; SPR, surface plasmon res-
or.
@nju.edu.cn (Y. Sun),
. This is an open access article underhepatic stellate cells (HSCs) which are the principal ﬁbrogenic cell
type in the liver (Bonner, 2004). Following chronic liver injury, HSCs dif-
ferentiate from quiescent cells into proliferative myoﬁbroblasts, which
are an activated type of HSCs (Bataller and Brenner, 2005). During this
transition, activated HSCs up-regulate the expression of PDGFR-β,
whereas the level of PDGFR-β is low in healthy livers (Bonner, 2004;
Kocabayoglu et al., 2015). Additionally, the paracrine signaling mole-
cules released by other resident liver cells can also enhance the expres-
sions of PDGF-B and PDGFR-β in activated HSCs (Bonner, 2004).
However, the level of PDGFR-α expression by HSCs remains unchanged
during liver injury (Bonner, 2004).
It is well known that PDGF-BB/PDGFR-ββ signaling is the most po-
tent mitogenic pathway in HSC activation and ﬁbrogenesis (Bonner,
2004; Kocabayoglu et al., 2015). Patients with liver cirrhosis caused by
chronic hepatitis C exhibit more extensive platelet areas in the liver
compared with normal livers, and HSCs expressing PDGFR-β are
frequently observed in the areas with extensive platelets (Kondo et al.,
2013). The PDGF-BB/PDGFR-ββ axis represents an appealing target for
the treatment of liver ﬁbrosis (Kocabayoglu et al., 2015; Prosser et al.,
2006; Yoshida et al., 2014); speciﬁcally, antagonism of this axis has
the potential to serve as an anti-ﬁbrotic strategy. Previous studies
have revealed that some receptor tyrosine kinase inhibitors, such as i-
matinib, sorafenib and sunitinib, whose targets include PDGFR-β, inhib-
it HSC activation and mitigate ﬁbrosis (Majumder et al., 2013; Westra
et al., 2014). However, these drugs are nonselective PDGFR-β inhibitors
that were originally used to treat cancers in the clinic (Ehnman andthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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patients affected only by the PDGFR-β-related diseases. In order to
make anti-ﬁbrotic drugs selectively target the activated HSCs,
Brennand et al. constructed a cyclic peptide analog of PDGF-BB73–81
(77IVRKK81-C-73RKIE78) that can prevent PDGF-BB from binding to
its receptor and inhibit PDGF-BB-induced DNA synthesis in human
ﬁbroblasts (Brennand et al., 1997), whereas there are no data to sup-
port its in vivo effects. Beljaars et al. constructed a macromolecule
with afﬁnity for PDGFR-β by modiﬁcation of human serum albumin
(HSA) with a cyclic octapeptide (called pPB) that recognizes the
PDGFR-β (Beljaars et al., 2003). This macromolecule (pPB-HSA) is
able to reduce PDGF-BB-induced ﬁbroblast proliferation in vitro
(Beljaars et al., 2003). However, pPB alone has no ability to compete
with the cellular binding of PDGF-BB within 0–125 μM (Beljaars et al.,
2003). Notably, pPB-HAS and bicyclic pPB fail to exert anti-ﬁbrotic effects
onmice administeredwith CCl4 (Bansal et al., 2011, 2014). Therefore, pPB
and BipPBmodiﬁed proteins are predominantly used as targeting devices
to selectively interact with cells, predominantly (myo) ﬁbroblasts, that
express the PDGF-β receptor (Bansal et al., 2011, 2014; Beljaars et al.,
2003). Therefore, more efﬁcacious and selective drug candidates
targeting the PDGF-BB/PDGFR-ββ axis are still lacking. These consider-
ations impelled us to explore an alternative therapeutic approach to
more selectively block the PDGF-BB/PDGFR-ββ axis. After screening of
multiple compounds, we found that destruxin A5, a natural cyclopeptide
which has insecticidal and anti-inﬂammatory effects (Krasnoff et al.,
1996; Zhang et al., 2013), represents a therapeutic option for liverﬁbrosis.
Herein, we describe a highly efﬁcacious inhibitory approach involving
destruxin A5 to selectively block PDGF-BB/PDGFR-ββ signaling by
targeting PDGFR-β to occupy the protein–protein binding interface be-
tween PDGF-B and PDGFR-β.
2. Materials and Methods
2.1. Mice and Reagents
Destruxin A5was isolated and identiﬁed as reported by us previous-
ly (Zhang et al., 2013). Detailed information on mice and reagents is
provided in the Supplemental Experimental Procedures.
2.2. Cell Culture and Cell Proliferation Assay
The immortalized human HSC line LX-2 and activated rat HSC line
CFSC-8B were maintained in new plastic culture dishes in Dulbecco's
modiﬁed Eagle'smedium supplementedwith 100 μg/ml of streptomycin,
100 U/ml of penicillin and 10% fetal bovine serum (FBS) under a humid-
iﬁed 5% (v/v) CO2 atmosphere at 37 °C. Cell proliferationwas determined
by MTT assay, as we have previously reported (Wang et al., 2014).
2.3. Surface Plasmon Resonance (SPR)
We performed SPR assays using the Biacore T200. Detailed informa-
tion is provided in the Supplemental Experimental Procedures.
2.4. HSC Migration Assay
The migratory capacities of the cells were investigated as described
previously (Liu et al., 2011). Detailed information is provided in the Sup-
plemental Experimental Procedures.
2.5. HSC Wound Healing Assay
For the determination of cell migration during wound healing, a
wound healing assay was performed as described previously
(Rodriguez et al., 2005). Detailed information is provided in the Supple-
mental Experimental Procedures.2.6. Western Blot
Proteinswere extracted in lysis buffer. The proteinswere then sepa-
rated by SDS-PAGE (10%) and electrophoretically transferred onto
polyvinylidene ﬂuoride membranes. The membranes were probed
with antibodies overnight at 4 °C, and then incubated with a HRP-
coupled secondary antibody. Detectionwas performed using a LumiGLO
chemiluminescent substrate system (KPL, Guildford, UK).2.7. Cell Cycle Assay
This work was performed as we previously reported (Wang et al.,
2015b). Detailed information is provided in the Supplemental Experi-
mental Procedures.2.8. Cell Apoptosis Assay
HSCs were seeded in 6-well plates in Dulbecco's modiﬁed Eagle's
medium and treatedwith orwithout destruxin A5 for 24 h. Cell apopto-
sis was determined by ﬂow cytometry after addition of FITC-conjugated
annexin V and PI assay. Sampleswere analyzed by ﬂow cytrometry on a
FACScan (Becton Dickinson). Data were analyzed with CELLQuest
software (BD Biosciences).2.9. Immunohistochemistry
Parafﬁn-embedded liver sections were heat-ﬁxed, blocked with 3%
H2O2, and incubated with speciﬁc antibodies (1:100 diluted) overnight
at 4–8 °C. Detection was done using Real Envision Detection kit from
GeneTech Company (Shanghai, China) according to the manufacturer's
instructions.2.10. Real-time Quantitative PCR
This work was performed as we previously reported (Wang et al.,
2015a). Detailed information is provided in the Supplemental Experi-
mental Procedures.2.11. Cultivation and Metabolites Isolation
Detailed information is provided in the Supplemental Experimental
Procedures.2.12. Models of Murine Liver Fibrosis
Liver ﬁbrosiswas induced by ligation of the common bile duct (BDL)
(Liu et al., 2011).Mice (8–10weeks, n=8 in each group)were anesthe-
tized. Followingmidline laparotomy, the common bile duct was double
ligated and transected between the ligatures. The sham group was
subjected to a similar operation without BDL. After BDL for 6 d,
destruxin A5 was administered at 5–10 mg/kg/d for another 8 d. Mice
that underwent BDL for 6 d and 14 d served as controls for the destruxin
A5 treatment.2.13. Statistical Analysis
All results shown represent means ± SEM. From triplicate experi-
ments performed in a parallel manner. Data were statistically evaluated
by one-way ANOVA followed by Dunnett's test between control group
and multiple dose groups. The level of signiﬁcance was set at a P value
of 0.05.
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3.1. Destruxin A5 Inhibited PDGF-BB/PDGFR-ββ Signaling via a Different
Mechanism than Tyrosine Kinase Inhibitors
To assess the inﬂuences of natural cyclopeptides including destruxin
A5, trichomide C, roseocardin, homodestcardin, trichomide A,
trichomide B, destruxin B and homodestruxin B (Fig. 1A and Supple-
mentary Fig. 1) on PDGF-B/PDGFR-β signaling, the cellular expression
levels of phosphorylated PDGFR-β, AKT and ERK were examined. Stim-
ulation of the rat HSC line CFSC-8B with 10 ng/ml of PDGF-BB for 15–
30 min led to the increased expression of p-PDGFR-β and its down-
stream signaling proteins, including p-AKT and p-ERK (Fig. 1B, C, and
Supplementary Fig. 3). Western blotting also revealed that only
destruxin A5 dose-dependently reduced the levels of p-PDGFR-β, p-
AKT and p-ERK in PDGF-B-stimulated cells (Fig. 1B and C), whereas
destruxin A5 had no effects on the phosphorylation of PDGFR-β, AKT
and ERK in cells not stimulated with PDGF-B (Supplementary Fig. 2).
Notably, destruxin A5 does not have the ability to bind to the ATP-
binding pocket of tyrosine kinase domain when we tested the effect of
destruxin A5 on the activated intracellular tyrosine kinase domain of
human PDGFR-β (Fig. 1D). In contrast, sunitinib, which is a well-
known tyrosine kinase inhibitor, displayed a very obvious inhibitory
effect on the kinase activity of human PDGFR-β (Fig. 1D). Additionally,
because no crystal structure of the intracellular tyrosine kinase domain
of human PDGFR-β is available in the RCSB Protein Data Bank,we used a
homology model/docking approach to measure the computational
binding ability of destruxin A5 to the intracellular tyrosine kinase do-
main of human PDGFR-β using sunitinib as the positive control. Accord-
ing to the protocol published byHorbert, theDFG-in homologymodel of
the intracellular tyrosine kinase domainwas established using the crys-
tal structure of VEGFR2 as the template (Horbert et al., 2015) (Supple-
mentary Fig. 4A). Using the established model, the computational
binding results from the AutoDock 4.2 software revealed that sunitinib
exhibited a good afﬁnity for the ATP-binding pocket of human PDGFR-
β, and the modeled binding mode of sunitinib in PDGFR-β could be
overlaid on its crystal structure form in VEGFR2 (Supplementary Fig.
4B), which suggests that this homology model could be used to testFig. 1. PDGF-BB/PDGFR-ββ signaling was inhibited by destruxin A5. (A) The chemical structure
eachgroup) of expression of PDGF-BB/PDGFR-ββ signaling-relatedproteins. Thewestern blottin
β activity was determined using the PDGFR-β activity assay kit (n= 6 each group). The data are
⁎P b 0.05, ⁎⁎P b 0.01 versus the control group.the computational binding ability of destruxin A5 to the ATP-binding
pocket of human PDGFR-β. The calculated results indicated that
destruxin A5 had no direct ligand-protein interaction with the ATP-
binding pocket (data not shown), which is consistent with the kinase
activity result.
3.2. Destruxin A5 was Able to Bind to the Extracellular Domain of Human
PDGFR-β and Disrupt the Interaction Between PDGF-BB and PDGFR-β
To examine whether the extracellular domain of human PDGFR-β
(Met 1-Lys 531) contained the binding site for destruxin A5, we used
Biacore surface plasmon resonance (SPR), which is a novel and straight-
forward methodology for to study compound-protein interactions.
Fig. 2A illustrates the binding of destruxin A5 to human PDGFR-β (Met
1-Lys 531), as captured on the sensor chip surface at 7200 relative
units (RU). These results demonstrated that the responses observed
for destruxin A5 correlated with its density. The rate constants of the
Biacore T200 yielded an afﬁnity for the destruxin A5/PDGFR-β interac-
tion of 4.92 μM (Fig. 2A). Additionally, protein thermal shift technology
and microscale thermophoresis technology were also used to strength-
en the support for a destruxin A5/PDGFR-β interaction. These results in-
dicated that destruxin A5 could bind to the extracellular domain of
human PDGFR-β, leading to a protein thermal shift and a KD value
from the microscale thermophoresis of approximately 5.43 μM, which
is consistent with the afﬁnity yield by SPR (Supplementary Fig. 5). The
reliability of Biacore's thermodynamic analysis has been conﬁrmed in
many studies (Bai et al., 2013; Papalia et al., 2008; Suzuki et al., 2009;
Wear and Walkinshaw, 2006). Herein, the Biacore T200 technology
was used to characterize the thermodynamic parameters of the binding
of destruxin A5 to the extracellular domain of human PDGFR-β via
conjunction with a Van't Hoff analysis (Supplementary Table 1).
Analysis based on the Van't Hoff equation indicated that the thermody-
namic parameters determined by SPR at 25 °C were as follows:
KD ≈ 8.02 μM, △Go ≈ −6.95 kcal·M−1, △Ho ≈ −2.28 kcal·M−1,
T△So≈ 4.66 kcal·M−1 and△CP≈ 1.04 kcal·K−1·M−1. These ﬁndings
also indicated that destruxin A5was able to bind to the extracellular do-
main of humanPDGFR-β. Additionally, the SPR results indicated that the
other natural cyclopeptides evaluated in this study minimally bound toof destruxin A5. (B and C) Representative western blot bands and a data summary (n= 4
gdata are presented as themeans±SEM. (D) Theeffect of destruxin A5onhuman PDGFR-
expressed as histogram containing themeans± SEM. of three independent experiments.
Fig. 2. Destruxin A5 bound to human PDGFR-β (Met 1-Lys 531) protein and blocked the interaction between PDGF-BB and PDGFR-β. (A) Destruxin A5 associated with human PDGFR-β
(Met 1-Lys 531) protein as measured by SPR analysis. (B) The inhibitory effect of destruxin A5 on the PDGF-B/PDGFR-β interaction was evaluated using the single-cycle kinetic
methodology of SPR. (C and D) Destruxin A5 blocked the interaction between PDGF-BB and PDGFR-β, as measured with SPR. (E) Destruxin A5 promoted the dissociation of PDGF-BB
from PDGFR-β. (F) Destruxin A5 blocked PDGFR-β dimerization induced by PDGF-BB in the cellular system, as measured by non-denaturing western blotting. The data represented
here represent one of three independent experiments with similar results.
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A5 was unable to interact with PDGF-B (Supplementary Fig. 7). Using
the single-cycle kinetic methodology of the Biacore T200 to test the in-
ﬂuence of destruxin A5 on the PDGF-BB/PDGFR-β interaction, we found
that the response of PDGF-BB to PDGFR-β was markedly decreased by
destruxin A5 at 10 μM (Fig. 2B). When we measured the responses of
admixtures (40 ng/ml PDGF-BB with different concentrations of
destruxin A5) to PDGFR-β, the response values were found to be signif-
icantly reduced by destruxin A5 in a dose-dependentmanner compared
with the only PDGF-BB group, and the inhibitory effect of destruxin A5
was weakened by the 3-fold higher concentration of PDGF-BB (Fig. 2C
and D). In addition to the inhibitory effect of destruxin A5 on the bind-
ing process of PDGF-BB to PDGFR-β, destruxin A5 (10 and 50 μM) also
promoted the dissociation of PDGF-BB from PDGFR-β (Fig. 2E). It is
also known that PDGF-BB can enhance the conformation of PDGFR-ββ
(Bonner, 2004; Shim et al., 2010). Accordingly, non-denaturingwestern
blotting revealed that the PDGF-BB-induced PDGFR-β dimerization
(PDGFR-ββ) in cultured HSCs was blocked by destruxin A5, which
further conﬁrmed the SPR results in our cellular system (Fig. 2F).
3.3. Destruxin A5 Selectively Blocked PDGF-BB/PDGFR-ββ Signaling by
Targeting and Occupying the Binding Sites of PDGF-B with PDGFR-β
To identify the site in the extracellular domain of human PDGFR-β to
which destruxin A5 bound, we created a series of amino acid mutations
in the human PDGFR-β protein based on the binding amino acids of the
PDGF-B/PDGFR-β interface. We ﬁltered the afﬁnities of destruxin A5 to
different mutated human PDGFR-β proteins using Biacore's SPR meth-
odology. The SPR results demonstrated that the KD value of the
Phe136/Ala136 and Phe138/Ala138 mutated group was 99.5 μM,
which was approximately 20.2-fold higher than that of the wild-type
human PDGFR-β protein (Fig. 3A). This result indicated that Phe136
and Phe138 in human PDGFR-β contribute to the afﬁnity of the
destruxin A5/PDGFR-β interaction and that the binding sites ofdestruxin A5 in human PDGFR-β were the sites of the binding of
PDGF-B. PDGF-B was able to ﬁrmly bind to wild-type PDGFR-β
(Fig. 3B), whereas it minimally bound to Phe136/Ala136 and Phe138/
Ala138 mutated forms of PDGFR-β (Fig. 3C), which revealed that muta-
tions in Phe136 and Phe138 could strongly inﬂuence the PDGF-B/
PDGFR-β interaction. Additionally, analysis with the AutoDock 4.2 soft-
ware also indicated interactions between destruxin A5 and amino acids,
including Phe136 and Phe138 (Fig. 3D). Notably, the inhibitory effect of
destruxin A5 on PDGF-BB/PDGFR-ββ signaling was not related to
PDGFR-β endocytosis because destruxin A5 induced minimal PDGFR-β
endocytosis in CFSC-8B cells, as measured with ﬂow cytometry and
western blotting (Supplementary Fig. 8). Importantly, destruxin A5 ex-
hibited no abilities to bind to the extracellular domains of human
PDGFR-α, VEGFR1, VEGFR2, FLT3, KIT, EGFR or IFN-γR1 (Fig. 4). Further-
more, destruxin A5 exhibited an inhibitory effect on the growth of
PDGF-BB-stimulated HepG-2 cells and OS-RC-2 cells, with sunitinib as
the positive control (Supplementary Fig. 9). However, destruxin A5
minimally inhibited the cell proliferation induced by PDGF-AA, VEGF,
FLT3 ligand and KIT ligand (Supplementary Fig. 10).
3.4. Destruxin A5 Suppressed PDGF-BB-induced HSC Activation,
Proliferation, Migration, Cell Cycle Progression and Fibrosis-related Protein
Expression In Vitro
To observe the effects of destruxin A5 on PDGF-BB/PDGFR-ββ signal-
ing in a cellular system, cell activation, proliferation,migration, cell cycle
progression and ﬁbrosis-related protein expression were examined in
our study. As shown in Fig. 5A, destruxin A5 exhibited a minimal effect
on cell viability in PDGFR-β low-expressed LX-2 cells during their quies-
cent phase (cultured LX-2 cells were quiescent during the ﬁrst 3 d of
culture (Li et al., 2014)). However, destruxin A5 dose-dependently
inhibited the proliferation of PDGF-BB-activated LX-2 cells and PDGF-
BB-stimulated CFSC-8B cells (Fig. 5B–D). HSCs can migrate in response
to PDGF-BB stimuli (Patsenker et al., 2007). Not only cell proliferation
Fig. 3.Destruxin A5 occupied the interface between PDGF-BB and PDGFR-β. (A) The binding abilities of destruxin A5 to humanPDGFR-β (Met 1-Lys 531) proteinswith the Phe136/Ala136
and Phe138/Ala138 mutations were measured by SPR. (B and C) PDGF-BB associated with human PDGFR-β (Met 1-Lys 531) protein with or without the Phe136/Ala136 and Phe138/
Ala138 mutations, as measured with SPR. (D) The computational binding mode of destruxin A5 in human PDGFR-βwas established using AutoDock 4.2 software. The data represented
here represent one of three independent experiments with similar results.
Fig. 4. Destruxin A5 was unable to bind to the extracellular domains of human PDGFR-α, VEGFR1, VEGFR2, FLT3, KIT, EGFR or IFN-γR1. The binding abilities of destruxin A5 to the
extracellular domains of human PDGFR-α, VEGFR1, VEGFR2, FLT3, KIT, EGFR and IFN-γR1 were measured by SPR. The responses of destruxin A5 to these proteins were very weak,
which indicated that destruxin A5 did not directly interact with these proteins. The data represented here represent one of three independent experiments with similar results.
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Fig. 5.DestruxinA5 promoted antiﬁbrotic effects in vitro. (A) The effect of destruxin A5on the survival of quiescent LX-2 cellswas assessedwith theMTT assay (n=8 each group). The cell
proliferation-inhibiting effects of destruxinA5on PDGF-BB-activated LX-2 cells (n=8 eachgroup) (B) andCFSC-8B cells (n=8 eachgroup) (C)were evaluated usingMTT assays. (D) The
effects of destruxin A5 on CFSC-8B migration induced by PDGF-BB were appraised according to the linear wound repair capacity. (E and F) Representative western blot bands and a data
summary (n= 4 each group) of expression of cycle-related proteins. These proteins in CFSC-8B cells were down-regulated by destruxin A5. (G and H) Destruxin A5 induced apoptosis in
CFSC-8B cells (n=4 each group). (I and J) Representativewesternblot bands and a data summary (n=4 each group) of expression ofα-SMA, Col1A1 and Col3A1. These proteins in CFSC-
8B cells were decreased by destruxin A5. The data are expressed as a histogram illustrating the means ± SEM. of three independent experiments. ⁎P b 0.05, ⁎⁎P b 0.01 versus the control
group.
151X. Wang et al. / EBioMedicine 7 (2016) 146–156but also cell migration can be tested by wound healing assay (Fig. 5D).
PDGF-BB enhanced themigration of HSCs to repair linearwounds creat-
ed in cultured CFSC-8B cells (Fig. 5D). However, destruxin A5 effectivelyprevented the migration of HSCs via the blockade of PDGF-BB/PDGFR-
ββ signaling (Fig. 5D). Using other cell lines to conﬁrm the inhibitory ef-
fect of destruxin A5 on migration, the suppression of wound repair and
152 X. Wang et al. / EBioMedicine 7 (2016) 146–156cell invasion was also observed in PDGF-BB-treated OS-RC-2 cells (Sup-
plementary Fig. 11). However, the other natural cyclopeptides were un-
able to block PDGF-BB/PDGFR-ββ signaling and minimally inhibited
CFSC-8B cell migration (Supplementary Fig. 12). PDGF-BB stimulated
cell cycle progression in LX-2 cells, which was blocked by destruxin
A5 in a concentration-dependent manner (Supplementary Fig. 13);
this effect was also blocked in the PDGF-BB-treated OS-RC-2 cells (Sup-
plementary Fig. 14). Additionally, the expression levels of cell cycle
proteins, including p-Rb and Cyclin-D1, were reduced by destruxin A5
treatment (Fig. 5E and F). Moreover, destruxin A5 increased apoptosis
(Fig. 5G and H) and decreased the protein expression of liver ﬁbrosis-
related α-SMA, Col1A1 and Col3A1 in PDGF-BB-activated HSCs (Fig. 5I
and J).
3.5. Destruxin A5 Attenuated Bile Duct Ligation (BDL)-induced Liver
Fibrosis by Blocking PDGF-BB/PDGFR-ββ Signaling
Next, we veriﬁed the unique inhibitory effect of destruxin A5 on
PDGF-BB/PDGFR-ββ signaling in vivo. Six days after BDL surgery, liver
injury and ﬁbrosis were observed in operated mice. These conditions
became more severe in the subsequent 8 d of BDL, as conﬁrmed by
hematoxylin–eosin staining, Masson trichrome staining and immuno-
histochemistry (Fig. 6A–C and Supplementary Fig. 15). However, theFig. 6.Destruxin A5mitigated BDL-induced liver ﬁbrosis inmice (n= 8 in each group). (A) Effe
hematoxylin–eosin and examined by a blinded histologist (original magniﬁcation × 200). (B) E
stained with Masson and examined by a blinded histologist (original magniﬁcation × 200
immunohistochemical staining with α-SMA. The data represented here represent one
hydroxyproline content, total bilirubin content in serum, ALT content in serum and AST cont
the means ± the SEM. of three independent experiments. ⁎P b 0.05, ⁎⁎P b 0.01 versus the BDL 1therapeutic administration of destruxin A5 clearly ameliorated the
liver injury and reduced the accumulation of ﬁbrosis (Fig. 6A, B and Sup-
plementary Fig. 15). The anti-ﬁbrotic property of destruxin A5 in BDL-
treated mice was further veriﬁed by evaluating the effect of destruxin
A5 on α-SMA protein expression using immunohistochemistry
(Fig. 6C). The therapeutic administration of destruxin A5markedly mit-
igated the expression of α-SMA in BDL-induced liver ﬁbrosis compared
with the control group (Fig. 6C). Additionally, we assessed the spleen
weight/bodyweight ratio, content of hydroxyproline, serum total biliru-
bin, and serum alanine aminotransferase (ALT) and aspartate amino-
transferase (AST) levels to provide further evidence of the anti-ﬁbrotic
properties of destruxin A5 in BDL-treated mice (Fig. 6D). As shown in
Fig. 6D, the spleen values were dramatically decreased in animals with
experimental liver ﬁbrosis following therapeutic treatment with
destruxin A5, and the hydroxyproline content was also reduced in
BDL-treated mice after therapeutic destruxin A5 treatment. Additional-
ly, the levels of serum total bilirubin, ALT and AST were also evidently
decreased after the therapeutic administration of destruxin A5 to
animals with BDL-induced liver ﬁbrosis (Fig. 6D). To further explore
the mechanism by which destruxin A5 improved the BDL-induced
liver ﬁbrosis, we accessed the expression of PDGFR-β, p-PDGFR-β,
PDGFR-α, p-AKT, p-ERK, α-SMA and PDGF-BB in the ﬁbrotic livers. Im-
munohistochemical examination revealed that the protein expressioncts of destruxin A5 on liver ﬁbrosis in BDL mice. Sections of mouse liver were stained with
ffect of destruxin A5 on collagen expression in mice with liver ﬁbrosis. Liver sections were
). (C) Effect of destruxin A5 on α-SMA expression in mice with liver ﬁbrosis. Hepatic
of three independent experiments with similar results. (D) The spleen index, liver
ent in serum were tested in this study. The data are expressed as histograms illustrating
4 d group.
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this expression was suppressed by destruxin A5 therapeutic treatment
(Fig. 7A). The western blot results demonstrated that PDGFR-β expres-
sionwas highly induced in ﬁbrotic livers, whereas PDGFR-αwas consti-
tutively expressed in the normal livers and ﬁbrotic livers. Additionally,
the phosphorylation of PDGF-BB/PDGFR-ββ signaling-associated
proteins, including PDGFR-β, AKT and ERK, was down-regulated by
therapeutic treatment with destruxin A5. The expression level of α-
SMA was also decreased by destruxin A5, although this therapeutic
treatmentwas unable to reduce the level of PDGF-BB in BDL-induced ﬁ-
brotic livers (Fig. 7B and C). In addition to the in vivo examination, we
used precision-cut liver slices and a well-known tissue model for the
early onset of liver ﬁbrosis to test the efﬁcacies of antiﬁbrotic drugs
(Westra et al., 2014) and to evaluate the inhibitory effects of destruxin
A5 on PDGF-BB/PDGFR-ββ signaling. The q-PCR results revealed thatFig. 7. Effects of destruxin A5 on the expression of p-PDGFR-β, PDGFR-β, PDGFR-α, p-Akt, Akt, p
BDL (n=8 in each group). (A) Hepatic immunohistochemical stainingwith p-PDGFR-β antibod
results. (B and C) Total lysates from liver specimens of the control and destruxin A5-treated
illustrating the means ± SEM. of three independent experiments. ⁎P b 0.05, ⁎⁎P b 0.01 versus ththemRNA levels ofα-SMA, Col1A1 andHSP47 in the liver sliceswere in-
creased by PDGF-BB treatment but decreased by destruxin A5 (Supple-
mentary Fig. 16).
3.6. p-PDGFR-βwas Expressed in the Liver Tissues of Patients with Cirrhosis
Hepatitis B virus (HBV) can cause chronic liver injury resulting in
liver ﬁbrosis, and the end stage consequence of liver ﬁbrosis is liver
cirrhosis (Bataller and Brenner, 2005; Bonner, 2004; Kocabayoglu
et al., 2015). To test whether phosphorylated PDGFR-β is expressed in
hepatic tissue with cirrhosis, cirrhotic liver samples were obtained
from 62 HBV-positive patients, and samples from 35 human normal
controlswere used as the control group. The immunohistochemistry re-
sults revealed that the 37 cirrhotic liver samples expressed p-PDGFR-β
in the ﬁbrotic areas, whereas the normal hepatic tissue samples-ERK, ERK,α-SMA, PDGF-BB andGAPDH in the livers ofmicewith liver ﬁbrosis induced by
y. The data represented here represent one of three independent experimentswith similar
groups were subjected to western blot analysis. The data are expressed as histograms
e BDL 14 d group.
154 X. Wang et al. / EBioMedicine 7 (2016) 146–156expressed minimal p-PDGFR-β (Fig. 8), which indicated that p-PDGFR-
β-positive cells may represent an important hallmark and therapeutic
target for liver ﬁbrosis.
4. Discussion
PDGF-BB/PDGFR-ββ signaling is a druggable target whose inhibition
mitigates liver ﬁbrosis severity (Liu et al., 2011). Several strategies to
block PDGF-BB/PDGFR-ββ signaling have been applied in scientiﬁc re-
search on liver ﬁbrosis. For instance, PDGF-B monoclonal antibody, ade-
noviral dominant-negative soluble PDGFR-β and HSCs-speciﬁc PDGFR-β
small interference RNA have been developed to inhibit PDGF-BB/
PDGFR-ββ signaling to ameliorate liver ﬁbrosis in rodent disease models
(Chen et al., 2008; Reichenbach et al., 2012; Yoshida et al., 2014). Current-
ly approvedmedical therapies acting throughPDGF-BB/PDGFR-ββ inhibi-
tion are based onmulti-targeting tyrosine-kinase inhibitors (Ehnman and
Östman, 2014; Grassot et al., 2006; Horbert et al., 2015; Westra et al.,
2014). Although monoclonal antibodies possess a selective afﬁnity for
their target, they also have limitations (Miller et al., 2013; Mócsai et al.,
2014). Small-molecule inhibitors offer unique advantages, but they are
usually nonselective or less selective (Ehnman and Östman, 2014;
Horbert et al., 2015;Mócsai et al., 2014). Thus, the identiﬁcation or design
of small-molecule inhibitors with increased selective afﬁnity to PDGFR-β
represents an active area of research.
Notably, every tyrosine kinase receptor has a unique extracellular do-
main for its own ligand, which constitutes a distinct protein–protein in-
teraction interface between a ligand and its tyrosine kinase receptor. If
we could identify a small-molecule compound that targets the PDGF-B/
PDGFR-β interaction interface, it may serve as a selective inhibitor ofFig. 8. The expression of p-PDGFR-β in cirrhotic liver samples from 62HBV-positive patients and
staining with p-PDGFR-β antibody, (A) Representative staining from normal controls, and (B)PDGFR-β. However, modulating protein–protein interactions with small
organic compounds remains enormously challenging because the inter-
face areas are typically large (generally, an average interface area is
close to 1150–10,000 Å2) and ﬂat (Ivanov et al., 2013). Additionally, the
interface areas are typically hydrophobic and often lack the deep grooves
that provide an interface for small molecule docking (Ivanov et al., 2013).
Utilizing the proangiogenic VEGF/VEGFR protein–protein interface
(Gautier et al., 2011) and the oncogenic ERK/ERK protein–protein inter-
face (Herrero et al., 2015), researchers have found drug-like small mole-
cules using structure-based screening,which could speciﬁcally inhibit the
formation of the VEGFR1/VEGF complex and the dimeric ERK/ERK com-
plex (Gautier et al., 2011; Herrero et al., 2015). These successful reports
inspired us to search for a more selective inhibitor of PDGFR-β based on
the PDGF-B/PDGFR-β interaction interface.
Fortunately, we found that destruxin A5, a natural cyclopeptide, had
the ability to block PDGF-BB/PDGFR-ββ signalingwithout binding to the
ATP-binding pocket of human PDGFR-β, as observed with tyrosine
kinase inhibitors (Fig. 1). This interesting and puzzling phenomenon
attracted our attention. Surprisingly, destruxin A5 was able to bind to
the extracellular domain of human PDGFR-β but did not directly inter-
act with PDGF-BB (Fig. 2, Supplementary Fig. 5 and Supplementary
Fig. 7). Importantly, destruxin A5 was able to block the interaction be-
tween PDGF-B and PDGFR-β and inhibit the dimerization of PDGFR-β
that is induced by PDGF-BB stimulation of HSCs (Fig. 2), which indicated
that the initiation of PDGF-B/PDGFR-ββ signaling was blocked by
destruxin A5. We were also eager to explore the mechanism by which
destruxin A5 was able to block the PDGF-B/PDGFR-β interaction. En-
couragingly, our results suggested that destruxin A5 binds to human
PDGFR-β via interactions with Phe136 and Phe138 (Fig. 3). It should35 normal controls was evaluated using tissuemicroarray. Hepatic immunohistochemical
cirrhotic liver samples.
155X. Wang et al. / EBioMedicine 7 (2016) 146–156be emphasized that the PDGF-B/PDGFR-β interface is formedby the side
chains of Phe136, Phe138, Tyr205, Tyr207 from PDGFR-β and Leu38,
Trp40, Ile75, Ile77, Pro82, Phe84 from PDGF-B (Shim et al., 2010). Addi-
tionally, the PDGFR-β sequences were highly conserved among mouse,
rat and human (Supplementary Fig. 17). The overall PDGFR-β sequence
similarity of mouse or rat with human PDGFR-β sequence was 92% and
between mouse and rat 98%. Importantly, the PDGFR-β sequences of
mouse, rat and human all contain Phe136, Phe138, Tyr205 and
Tyr207. These data demonstrate that destruxin A5 is a compound that
targets the PDGF-B/PDGFR-β interaction interface to block PDGF-BB/
PDGFR-ββ signaling in mouse, rat and human. In the current study,
one of our most important ﬁndingwas the selective inhibitory property
of destruxin A5 for PDGF-BB/PDGFR-ββ signaling, as destruxin A5 elicit-
ed no inhibitory effect on the kinase activity of the tyrosine kinase and
had no direct effects on the interactions with the extracellular domains
of human PDGFR-α, VEGFR1, VEGFR2, FLT3, KIT, EGFR or IFN-γR1
(Fig. 4), Moreover, destruxin A5 only slightly inhibited the cell prolifer-
ation induced by PDGF-AA, VEGF, FLT3 ligand and KIT ligand, whereas
the cell proliferation induced by PDGF-BB was dose-dependently sup-
pressed by destruxin A5 (Supplementary Fig. 9 and Supplementary
Fig. 10). Thus, our study conﬁrms the selective inhibitory effect of
destruxin A5 on PDGF-BB/PDGFR-ββ signaling. These ﬁndingsmay con-
fer substantial beneﬁts to liver ﬁbrosis patients. Indeed, our in vitro
studies validated the suppressive effect of destruxin A5 on PDGF-BB/
PDGFR-ββ signaling-mediated activation, proliferation, migration, cell
cycle progression and ﬁbrosis-related protein expression in HSCs
(Fig. 5). Apoptosis is an important mechanism to reduce the number
of activated HSCs (Liu et al., 2011). Thus, we evaluated the effect of
destruxin A5 on apoptosis and found that destruxin A5 signiﬁcantly in-
creased the level of apoptosis in activated HSCs (Fig. 5G and H). More-
over, the antiﬁbrotic effects of destruxin A5 on liver ﬁbrosis were
veriﬁed in ex vivo and in vivo models, and the mechanism underlying
the antiﬁbrotic effect of destruxin A5 was shown to be due to its selec-
tive inhibitory role in PDGF-BB/PDGFR-ββ signaling (Figs. 6, 7 and Sup-
plementary Fig. 16). Importantly, the unique therapeutic effect of
destruxin A5 on liver ﬁbrosis carries extremely important and potential
clinical signiﬁcance because p-PDGFR-β is wildly expressed in cirrhotic
liver tissues from HBV-positive patients (Fig. 8).
PDGF-BB/PDGFR-ββ signaling represents a key target for the treat-
ment of liver ﬁbrosis, and destruxin A5 is a small-molecule inhibitor
shown to possess efﬁcacious and more selective properties for this cru-
cial pathogenic component of liver ﬁbrosis. Additionally, destruxin A5
could also be used in the treatment of other PDGFR-β-related diseases,
such as cancer. Together, our results stimulate further interest in the
identiﬁcation of small-molecule compounds that possessmore selective
afﬁnity for single cell surface tyrosine kinase receptors.
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